Lead candidate AMC303 is being developed as a treatment for patients with advanced and metastatic squamous tumors, e.g. head and neck cancer, esophageal cancer, cervical cancer, and lung cancer. AMC303 has a high specificity for inhibiting CD44v6, a co-receptor required for signaling through multiple cellular pathways (c-Met, VEGFR-2, RON)
Member count: 1-10
Total raised: $8.392295M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | LBBW Ventu... | lbbwvc.de |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 31.08.2017 | Grant | $2.084142M | - | finsmes.co... |
| 14.12.2016 | Series B | $6.308153M | - | finsmes.co... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 31.08.2017 | amcure Rec... | amcure, a German biopharmaceut... | Germany | - | finsmes.co... |
| 15.12.2016 | Amcure rai... | German oncology biotech Amcure... | Biotech | - | fiercebiot... |
| 14.12.2016 | Term Sheet... | SAN DIEGO, DIVERSITY AND LEONA... | - | - | fortune.co... |
| 14.12.2016 | amcure Rai... | amcure, an Eggenstein-Leopolds... | Germany | - | finsmes.co... |